Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Calhoun

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Biometrics|April 21, 2020
Repeated measures random forests (RMRF): Identifying factors associated with nocturnal hypoglycemiaPeter Calhoun, Richard A Levine, Juanjuan Fan
Diabetes Technology & Therapeutics|March 6, 2024
Weight Gain and Glycemic Control in Adults with Type 1 Diabetes in the T1D Exchange RegistryRyan Bailey, Peter Calhoun, Satish K Garg
Diabetes Technology & Therapeutics|October 2, 2020
Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes StudyPeter Calhoun, David Price, Roy W Beck
Diabetes Technology & Therapeutics|September 28, 2012
Use of continuous glucose monitoring as an outcome measure in clinical trialsRoy W Beck, Peter Calhoun, Craig Kollman
Diabetes Technology & Therapeutics|December 23, 2021
Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal InsulinShichun Bao, Ryan Bailey, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|October 27, 2021
With or Without Residual C-Peptide, Patients with Type 2 Diabetes Realize Glycemic Benefits from Real-Time Continuous Glucose MonitoringRyan Bailey, Peter Calhoun, Christy Chao, et al.
Diabetes Technology & Therapeutics|June 4, 2013
Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetesPeter Calhoun, John Lum, Roy W Beck, et al.
Diabetes Technology & Therapeutics|December 28, 2022
The Relationship Between Percent Time <70 mg/dL and Percent Time <54 mg/dL Measured by Continuous Glucose MonitoringRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|April 13, 2023
Concordance of Central Laboratory Hemoglobin A1c Measurements from Capillary Kits Compared to Venous Draws in the Insulin-Only Bionic Pancreas Pivotal TrialZoey Li, Peter Calhoun, Katrina J Ruedy, et al.
Diabetes Technology & Therapeutics|September 21, 2022
Assessment of the Glucose Management Indicator Using Different Sampling DurationsRyan Bailey, Peter Calhoun, Richard M Bergenstal, et al.
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Biometrics|April 21, 2020
Repeated measures random forests (RMRF): Identifying factors associated with nocturnal hypoglycemiaPeter Calhoun, Richard A Levine, Juanjuan Fan
Diabetes Technology & Therapeutics|March 6, 2024
Weight Gain and Glycemic Control in Adults with Type 1 Diabetes in the T1D Exchange RegistryRyan Bailey, Peter Calhoun, Satish K Garg
Diabetes Technology & Therapeutics|October 2, 2020
Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes StudyPeter Calhoun, David Price, Roy W Beck
Diabetes Technology & Therapeutics|September 28, 2012
Use of continuous glucose monitoring as an outcome measure in clinical trialsRoy W Beck, Peter Calhoun, Craig Kollman
Diabetes Technology & Therapeutics|December 23, 2021
Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal InsulinShichun Bao, Ryan Bailey, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|October 27, 2021
With or Without Residual C-Peptide, Patients with Type 2 Diabetes Realize Glycemic Benefits from Real-Time Continuous Glucose MonitoringRyan Bailey, Peter Calhoun, Christy Chao, et al.
Diabetes Technology & Therapeutics|June 4, 2013
Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetesPeter Calhoun, John Lum, Roy W Beck, et al.
Diabetes Technology & Therapeutics|December 28, 2022
The Relationship Between Percent Time <70 mg/dL and Percent Time <54 mg/dL Measured by Continuous Glucose MonitoringRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|April 13, 2023
Concordance of Central Laboratory Hemoglobin A1c Measurements from Capillary Kits Compared to Venous Draws in the Insulin-Only Bionic Pancreas Pivotal TrialZoey Li, Peter Calhoun, Katrina J Ruedy, et al.
Diabetes Technology & Therapeutics|September 21, 2022
Assessment of the Glucose Management Indicator Using Different Sampling DurationsRyan Bailey, Peter Calhoun, Richard M Bergenstal, et al.
Pageof 10